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New Findings 
 What is the central question of this study? 
Glucocorticoids act in the kidney to promote salt and water retention.  Renal 11β-hydroxysteroid 
dehydrogenase type 1, by increasing local concentrations of glucocorticoids, may exert an anti-
natriuretic effect.  We hypothesised that global deletion of 11β-hydroxysteroid dehydrogenase type 1 
in the mouse would give rise to a salt-wasting renal phenotype.   
 What is the main finding and its importance? 
We subjected a mouse model of global 11βHSD1 deletion to studies of water and electrolyte 
balance, renal clearance, urinary steroid excretion, renin-angiotensin system activation and renal 
sodium transporter expression.  We found no significant effects on renal sodium or water excretion.  
Any effect of renal 11βHSD1 on sodium homeostasis is subtle.   
Abstract 
Glucocorticoids act in the kidney to regulate glomerular haemodynamics and tubular sodium 
transport; the net effect favours sodium retention.  11β-hydroxysteroid dehydrogenase type 1 
(11βHSD1) is expressed in the renal tubules and the interstitial cells of the medulla, where it is likely 
to regenerate active glucocorticoids from inert 11-keto forms.  The physiological function of renal 
11βHSD1 is largely unknown.  We hypothesised that loss of renal 11βHSD1 would result in salt 
wasting, and tested this in a knockout mouse model in which 11βHSD1 was deleted in all body 
tissues.  In balance studies, 11βHSD1 deletion had no effect on water, sodium or potassium 
metabolism; transition to a low sodium diet did not reveal a natriuretic phenotype.  Renal clearance 
studies demonstrated identical haemodynamic parameters (arterial blood pressure, renal blood flow, 
glomerular filtration rate) in knockout and wild-type mice, but revealed an augmented kaliuretic 
response to thiazides in 11βHSD1 knockouts.  There was no effect on the natriuretic response to the 
amiloride analogue benzamil.  Urinary excretion of deoxycorticosterone (DOC) was higher in 
11βHSD1 knockout mice and there was hypertrophy of cells in the zona fasciculata of the adrenal 
cortex.  There was no difference in the activity of the renin-angiotensin and nitric oxide systems, no 
difference in renal histology, and no difference in the abundance of key tubular transporter proteins.  
We conclude that any effect of 11βHSD1 on renal sodium excretion is subtle.   
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Introduction 
In the adult mammalian kidney, glucocorticoids regulate tissue haemodynamics (increasing renal 
blood flow and glomerular filtration rate), the production of vasoactive paracrine / endocrine factors 
and sodium transport in the renal tubule (Mangos et al., 2003; Hunter et al., 2014b).  These renal effects 
contribute to the regulation of total body sodium and systemic arterial blood pressure (ABP).   
In target tissues, glucocorticoid activity is determined by the density of nuclear glucocorticoid 
receptors (GR), circulating levels of glucocorticoids and the activity of 11β-hydroxysteroid 
dehydrogenase (11βHSD) enzymes.  11βHSD1 regenerates active glucocorticoids, catalysing the 
conversion of cortisone to cortisol in humans (11-dehydrocorticosterone to corticosterone in rodents); 
11βHSD2 catalyses the reverse reaction (Chapman et al., 2013).  Adipose-specific 11βHSD1 deletion in 
the mouse attenuates the metabolic consequences of circulating glucocorticoid excess, demonstrating 
that 11βHSD1 activity is a major regulator of local glucocorticoid activity, at least in adipose tissue 
(Morgan et al., 2014).   
Both 11βHSD1 and 11βHSD2 are expressed in the kidney.  11βHSD2 is expressed in the tubular 
cells of the distal renal tubule (connecting tubule and collecting ducts), where it prevents active 
glucocorticoids from binding and activating the mineralocorticoid receptor (MR).  MR can bind 
glucocorticoids and mineralocorticoids with high affinity in vitro (Arriza et al., 1987); 11βHSD2 thus 
acts to maintain the specificity of aldosterone-MR signalling in vivo.  11βHSD1 is expressed in the 
proximal tubule, macula densa and the interstitial cells of the renal medulla (Odermatt & Kratschmar, 
2012); its in vivo function at these sites is controversial.  Enzyme kinetic studies using homogenised 
kidney preparations suggest that 11βHSD1 may act as a dehydrogenase (i.e. converting cortisol to 
cortisone) (Gong et al., 2008).  However, siRNA-mediated knock-down of 11βHSD1 activity in the 
renal medulla results in reduced urinary excretion of corticosterone (Liu et al., 2008), consistent with 
the enzyme operating as a reductase in vivo (i.e. regenerating active glucocorticoid).   
The downstream physiological consequences of renal 11βHSD1 activity are largely unknown.  
However, two lines of evidence suggest that renal 11βHSD1 activity influences systemic blood 
pressure in rodents.  First, renal 11βHSD1 mRNA expression is higher in a salt-sensitive rat model 
(Dahl SS) than in a salt-resistant consomic strain (SS-13BN/Mcw).  This positive association between 
renal 11βHSD1 activity and systemic blood pressure is only apparent when the animals receive high 
dietary salt (Liang et al., 2003; Liu et al., 2008).  Second, knockdown of Hsd11b1 mRNA in the renal 
medulla of Dahl SS rats attenuates salt-sensitive hypertension (Liu et al., 2008), providing the most 
compelling evidence for a causal link between renal 11βHSD1 activity and blood pressure.  Moreover, 
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the renal expression of 11βHSD1 is modified by dietary sodium intake, implying that its activity may 
be regulated by factors directed at maintaining sodium homeostasis.  High dietary sodium reduces 
Hsd11b1 mRNA expression in rat proximal tubules (McKinnell et al., 2000) and in the renal medulla 
of salt-resistant rats (Liang et al., 2003; Liu et al., 2008).   
The literature therefore suggests that renal 11βHSD1 activity leads to increased systemic blood 
pressure, although the mechanism remains unknown.  Given that glucocorticoids can stimulate 
sodium reabsorption in the proximal nephron, distal nephron and collecting ducts (Hunter et al., 
2014b), we hypothesised that renal 11βHSD1 activity opposes natriuresis by regenerating active 
glucocorticoid in the renal tubules.  It follows that the global deletion of 11βHSD1 would result in a 
tendency to renal sodium loss, manifesting in a phenotype that would be subject to neurohormonal 
compensation from the RAAS, hypothalamo-pituitary-adrenal (HPA) axis, sympathetic nervous 
system and other natritropic regulators.   
The aim of this study was to assess the effect of global 11βHSD1 deletion on renal sodium 
transport and to determine the implicated neurohormonal / transport systems.  We subjected 
11βHSD1 knockout mice to perturbations in dietary sodium intake and examined the consequences 
for systemic sodium and water homeostasis, renal haemodynamics, renal sodium transport pathways 
and systemic steroidogenesis.   
Methods 
Ethical approval 
All experimental procedures were performed under UK Home Office licence in accordance with 
the Animals (Scientific Procedures) Act, 1986.  All experimental procedures involving live animals 
were reviewed and approved by local veterinary surgeons.   
Hsd11b1
–/–
 and wild-type mice 
Mice had free access to water and a standard RM1 diet (0.25% Na+; Special Diet Services, Witham, 
UK) unless otherwise stated, and were maintained on a 12 hour light-dark cycle.  Wild type control 
mice (C57BL/6J) were obtained from an in-house colony, derived from purchased stock (Harlan 
Laboratories, Loughborough, UK).  Male mice were used for all experiments.  Hsd11b1/ mice were 
the offspring of homozygous-homozygous crosses in a colony carrying a null mutation in the 
Hsd11b1 gene on the C57BL/6J background (Morton et al., 2004).  The gene mutation (originally 
introduced on an MF1 background) has been previously shown to completely ablate 11βHSD1 
activity in vivo and in vitro (Kotelevtsev et al., 1997).   
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Balance studies 
Mice were housed individually in metabolic cages that enabled the independent collection of urine 
and faeces and were left to acclimatise for five days before any experimental data were obtained.  
Drinking water and diet were provided ad libitum.  Animals were given gel diets to minimise diet 
dispersion and sample contamination.  Gel diet production was adapted from an existing method 
(Ahn et al., 2004).  Diets contained 36% ground diet (RM1; or low sodium diet, Ziegler Bros, Gardners, 
PA, USA), 3.8% bovine gelatine (Dr. Oetker Nahrungmittel, Bielefeld, Germany) and supplementary 
NaCl to make 0.026% Na+ (low-), 0.2% Na+ (normal-) and 2.1% Na+ (high-) sodium diets (percentages 
in dry weight equivalents).  Following acid digestion, the Na+ content of each diet was verified by 
flame photometry.   
During the study period, mice received control Na+ diet for 4 days and then either high or low Na+ 
diet for 8 days (Figure 1A).  Dietary intake, urine output and faecal output were measured over 24 
hour collection periods, each finishing immediately after the nocturnal active period.  At the end of 
the study period, animals were sacrificed by cervical dislocation and terminal blood and kidneys 
were snap-frozen and stored at – 80°C.   
Faecal samples were dried at 105°C for 24 hours to assess gastrointestinal water losses.  To 
measure faecal Na+ and K+ content, dried faecal samples were homogenised then digested in 
concentrated nitric acid (~15M; Fisher Scientific) for 24 hours at 65°C in an orbital shaker.  Digested 
faecal and urine samples were diluted in 10 ppm diluent concentrate (1% Brij35, BWB Technologies 
UK, Braintree, UK) 1:6 and 1:25-1:50, respectively before measurement of [Na+] and [K+] by flame 
photometry (BWB Technologies UK).   
Results were normalised to kidney weight (rather than body weight) because Hsd11b1/ mice 
differ from wild-types in their adipose tissue distribution (Morton et al., 2004).   
Renal clearance 
Renal clearance experiments were performed under terminal anaesthesia (Inactin, thiobutabarbital 
sodium salt hydrate, Sigma) as previously described (Hunter et al., 2014a).  Anaesthesia was induced 
with an intraperitoneal injection of c. 150 mg per kg body weight and maintained by repeated 
intravenous bolus injection at a level sufficient to suppress the blink reflex and a motor response to 
toe pinch (typical total dose 200 – 250 mg per kg body weight).  Catheters were inserted into the 
trachea, jugular vein, carotid artery and bladder.  A bolus dose (0.1 ml / 10 g body weight) of 
physiological saline solution was given via the jugular catheter as soon as intravenous access was 
established, followed by a continuous infusion of 0.2 ml / 10 g / hour with a solution containing (in 
mM): 146 Na+, 5 K+, 113 Cl–, 15 HCO3– and (in % w/v) 0.25 FITC-inulin, 0.5 PAH (p-Aminohippuric 
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acid sodium salt, Sigma), pH 7.4.  Mean arterial blood pressure was recorded from the carotid 
catheter in real time.   
Urine and blood samples were collected according to the protocol depicted in Figure 1B.  Mice 
were left to equilibrate for 60 minutes after surgery.  Urine was collected over a 40-minute baseline 
period, then an intravenous bolus dose of diuretic (either bendroflumethiazide or benzamil) at a dose 
of 2 mg per kg body weight in 1% DMSO was administered.  A 20-minute period of re-equilibration 
was followed by a second 40-minute urine collection.  ~70 µl blood samples were obtained from the 
arterial line at the end of the first equilibration period and after each urine collection; these were used 
to determine haematocrit, plasma [inulin] and [PAH].  At the end of the protocol, a 1 ml sample of 
blood was obtained for the measurement of plasma [Na+], [K+] and [Cl].  The surgeon was blinded to 
genotype until after all analyses were completed.   
The inulin, PAH and electrolyte assays were conducted as previously described (Hunter et al., 
2014a).  Briefly, [FITC-inulin] in plasma and urine was determined by measuring fluorescence 
intensity at pH 7.4, relative to a 9-point standard curve in duplicate.  [PAH] in plasma and urine was 
determined by a colorimetric method, relative to an 11-point standard curve in duplicate.  [Na+], [K+] 
and [Cl] were measured by an ion-sensitive electrode (Roche 9180 Electrolyte Analyzer).  Glomerular 
filtration rate (GFR), effective renal blood flow (eRBF) and the fractional excretion of electrolytes 
(FENa, FEK, FECl) were derived from inulin and PAH clearance, using standard equations (Hunter et 
al., 2014a).   
Urinary steroid and NOx analysis 
Urinary corticosterone, aldosterone and deoxycorticosterone (DOC) were measured by 
colorimetric ELISA as previously described (Al-Dujaili et al., 2009b, 2009a).  Briefly, urinary steroids 
were extracted in surplus 2-methoxy-2-methylpropane and re-constituted in assay buffer.  96-well 
plates were coated with steroid-albumin conjugates overnight (1.25 µg / ml; Steraloids, Newport, RI, 
USA).  The following reagents were then added in sequence (with intermediate washing steps): 
blocking buffer, standards in duplicate, samples in duplicate, primary antibody (sheep anti-
aldosterone at 1:30000; sheep anti-corticosterone at 1:20000 or rabbit anti-DOC at 1:20000, produced 
in-house), HRP-linked secondary antibody (donkey anti-sheep Ig at 1:11000 or goat anti-rabbit at 
1:11000, Sigma), substrate solution and stop solution.  Absorbance was measured at 450 nm.   
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The concentration of total urinary nitrite and nitrate (NOx) was measured by colorimetric assay 
(780001, Cayman Chemicals, Ann Arbor, MI, USA), according to the manufacturer’s instructions after 
diluting urine 1:60.   
Renin and angiotensinogen radioimmunoassay 
Renin and angiotensinogen concentrations were measured by radioimmunoassay of angiotensin I 
generated by incubating plasma with excess angiotensinogen substrate (for renin assay) or excess 
renin enzyme (for angiotensinogen measurements).  Plasma samples (diluted tenfold with assay 
buffer for angiotensinogen), with added substrate or enzyme, were incubated with angiotensin I 
antibody at 37 or 0 °C for 1 hour before the addition of ice-cold assay buffer.  Duplicate angiotensin I 
standards (11 points, 0-40ng/L) were incubated in parallel.  Sample and standard assay tubes were 
then equilibrated at 2 °C for 48 hours with added 125I angiotensin (PerkinElmer).  Free and bound 
angiotensin were separated by charcoal extraction and radioactivity in the free fraction was counted 
in a Wallac gamma counter.  Renin enzyme and angiotensinogen substrate were prepared from 
cytosolic extracts of mouse submandibular glands and from the plasma of nephrectomised rats 
respectively.  Results were expressed as the difference in angiotensin I values in tubes incubated at 37 
and 0 °C.   
Histology 
Kidneys were fixed in situ by perfusion fixation as previously described (Hunter et al., 2014c).  
Mice were sacrificed by vascular perfusion under terminal anaesthesia (sodium pentobarbital, 
Sagatal; Ceva Santé Animale, Libourne, France; 50 mg per kg body weight as an intra-peritoneal 
bolus).  The infra-renal aorta was cannulated to permit retrograde perfusion with a vent in the vena 
cava.  10 ml heparinised saline (20 units / ml in PBS) were infused followed immediately by 50 ml 
fixative (fresh 4 % PFA in PBS, pH 7.4), delivered at a rate of 15 ml / min by a Gilson Minipuls 3 
peristaltic pump.  The kidneys was removed, the poles cut off and discarded, and the central portion 
immersed in 4 % PFA at 4°C for 24 hours before being embedded in paraffin wax.  5 micron sections 
were cut in the transverse plane and either stained with haematoxylin-eosin or used for 
immunohistochemistry.   
Immunohistochemistry (detection of NCC) 
Tissue sections were de-waxed and hydrated through graded alcohols and then heated in the 
presence of 10 mM citrate, pH 6.0.  Indirect immunofluorescent detection of NCC was performed 
using rabbit anti-NCC (Millipore, AB3553) at 1:1000 dilution, with a biotinylated secondary antibody 
(swine anti-rabbit IgG, DAKO) at 1:250.  The binding sites of secondary antibodies were detected 
using a Streptavidin-HRP amplification step (Vectastain R.T.U. Elite ABC reagent) and DAB (3,3’-
diaminobenzidine).   
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Analysis of adrenal cell size 
Adrenals were collected from mice housed in metabolic cages.  After formalin fixation and careful 
dissection (to remove surrounding adipose tissue), they were embedded in paraffin blocks, sectioned 
and stained with haematoxylin and eosin.  Sections were analysed with a Zeiss Axioskop compound 
microscope using a Nikon Coolpix 995 camera and MCID imaging software.  Cross-sectional areas of 
cells in morphologically distinct regions of the cortex and medulla were estimated by counting the 
number of nuclei (150-200) in a defined field area.  The observer was blinded to genotype and dietary 
Na+ treatment.  Results were expressed as mean ± standard error of averages from triplicate 
measurements of sections from four adrenal glands / treatment group.   
Western blot analysis 
Kidneys were homogenised in a buffer containing phosphatase, kinase and protease inhibitors 
(250 mM sucrose,10 mM triethanolamine, 2 mM EDTA, 50 mM NaF, 25 mM Na β-glycerophosphate, 
5 mM Na pyrophosphate, 1 mM Na orthovanadate, 1 % Protease Inhibitor Cocktail Set III, 
Calbiochem ®, pH 7.6).  Supernatants from two 15 minute centrifugations at 4000 g were pooled to 
form a total cellular protein fraction free from gross cellular and nuclear debris.  Total protein 
concentration was measured using a commercial bicinchonic acid assay (Pierce/Thermo Scientific, 
Rockford, IL, USA).   
For high molecular weight protein targets (>100 kDa), protein samples were diluted in NuPAGE 
LDS sample buffer (Invitrogen/Life Technologies, Paisley, UK) and 50 mM dithiothreitol (DTT; 
Sigma).  After heating to 70°C for 15 mins, samples were loaded in NuPAGE Novex 3-8% Tris-Acetate 
gels (Invitrogen/Life Technologies) and electrophoresed for 75 min at 150 V.  For lower molecular 
weight targets, samples were diluted in Laemmli buffer and (after heating) loaded in 12% Precise 
Protein Gels (Pierce/Thermo Scientific) and electrophoresed for 65 min at 100 V.   
Samples were transferred to a PVDF membrane (Hybond P, GE Healthcare Life Sciences, Little 
Chalfont, UK) using semi-dry transfer cell (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) at 10V 
for 30 min.  Membranes were incubated with blocking buffer (5 % w/v non-fat dry milk powder / 0.2 
% v/v Tween-20 in PBS) on a rolling shaker at room temperature for 1 hr and then incubated with 
primary antibody overnight at 4°C.  Primary antibodies and their dilutions were: rabbit anti-NCC 
(Millipore, AB3553) at 1:1000; sheep anti-pT53-NCC (Division of Signal Transduction Therapy, 
Dundee University), at 1:500 (= 0.2 – 1.2 µg / ml); sheep anti-NKCC2 (DSTT, Dundee) at 1:10000; 
rabbit anti-ENaC-γ (Johannes Loffing, Zurich) at 1:5000; sheep anti-NDRG1 (DSTT, Dundee) at 1:515; 
sheep anti-pNDRG1 (DSTT, Dundee) at 1:150.  For Western blots designed to recognise pT53-NCC, 
the corresponding non-phosphorylated peptide was included in the solution of primary antibody at a 
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final concentration of 10µg / ml.  After three five-minute washes with wash buffer (0.2 % v/v Tween-
20 in PBS) the membrane was incubated with an HRP-conjugated secondary antibody for 1 – 2 hrs at 
room temperature and then washed again (three ten-minute washes).  Secondary antibodies and their 
dilutions were: goat anti-rabbit IgG-HRP (Santa-Cruz, sc-2030) at 1:2000; donkey anti-sheep IgG-HRP 
(Sigma, A3415) at 1:20000.  Peroxidase activity was revealed using SuperSignal® West Pico 
Chemiluminescent Substrate to expose photographic film.   
Films were photographed using a digital SLR camera (Nikon D40) with the exposure set to 
maximise dynamic range without significant pixel saturation.  Images were analysed in ImageJ 
(version 1.47v).  A rectangular region of interest (ROI) was drawn to encompass the entire vertical 
range of each lane and the area under this curve was taken as a measure of the band density.  No 
background subtraction step was applied.  The bottom portion of each gel was excised prior to 
transfer to the PVDF membrane and stained with Coomassie blue.  The density of each lane on the 
film was divided by the density of the corresponding Coomassie lane in order to correct for variation 
in the total amount of protein loaded for each sample.  The final data were normalised so that for each 
assay, the wild-type group had a mean value of 1.0.   
Statistical analysis 
Data were assessed for Gaussian distribution using D’Agostino & Pearson omnibus test or 
Shapiro-Wilk normality tests (for small n-numbers).  Analysis was carried out using unpaired 
Student’s t-test or 2-way ANOVA (with repeated measures) with Holm-Šídák post hoc test as 
appropriate on GraphPad Prism 6.0 Software.  P < 0.05 was considered significant.  Results are 
presented as ANOVA-derived p-values and mean ± 95 % confidence interval (CI) unless otherwise 
specified.   
Results 
Urinary electrolyte excretion in conscious Hsd11b1
/ and wild-type mice 
Net urinary electrolyte excretion was measured in conscious mice housed in metabolism cages.  
After acclimatisation and baseline measurements (on 0.2% Na+ diet), animals were transitioned to 
either high (2.1%) or low (0.026%) dietary sodium (Figure 1A).  Baseline characteristics are 
summarised in Table 1.  Hsd11b1/ mice had significantly higher body weight and kidney weight, 
compared to age-matched wild-type.  Heart weights did not differ between genotypes (wild-type: 
127.1 – 230.5 mg vs. Hsd11b1/ 149.8 – 178.8 mg; n=7/8; 95%CI; p=0.650 by unpaired t-test).   
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Dietary intake of food and water did not differ significantly between genotypes (the p-values for 
comparison between genotypes by 2-way ANOVA were as follows: in the low-Na+ cohort, p = 0.395 
for water intake and p = 0.234 for food intake; in the high-Na+ cohort, p = 0.428 for water intake and p 
= 0.208 for food intake).  Any variation in the balance data was dominated by changes in excretion of 
water, Na+ or K+ (raw data provided in Supplemental Table S1).   
Hsd11b1/ mice did not differ from wild-type controls in water balance, Na+ balance or K+ balance 
under basal conditions.  Nor were there any differences in their response to either dietary Na+ loading 
or restriction (Figure 2).  In the low-Na+ study (n = 12), Hsd11b1/ mice had reduced insensible losses 
of water and K+ (manifesting as a smaller positive 24 hr balance) under baseline conditions.  However, 
these differences were not replicated in the statistically more powerful (n = 22) high-Na+ study.  
Following transition to a high-Na+ diet, in both genotypes there was a transient period of positive Na+ 
balance during the first 4 days, until Na+ excretion was up-regulated to match intake (Figure 2B).   
Renal clearance under anaesthesia 
In order to resolve glomerular and tubular effects, renal function was investigated by renal 
clearance under terminal anaesthesia, in mice that had been maintained on a normal (0.2%) Na+ diet.  
Haemodynamic parameters (arterial blood pressure, ABP; renal blood flow, RBF; glomerular 
filtration rate, GFR), plasma electrolyte concentrations and urinary electrolyte excretion were 
measured at baseline (after an initial acclimatisation period) and after a bolus dose of 
bendroflumethiazide (BFTZ, 2 mg per kg body weight; Figure 1B).  BFTZ is an inhibitor of the NaCl 
co-transporter (NCC) in the distal convoluted tubule (DCT), a known target of glucocorticoid 
signalling (see discussion).   
Hsd11b1/ mice did not differ from wild-types in either the concentration of Na+, K+ and Cl in the 
plasma (Table 2).  There were no significant genotype-specific differences in ABP, RBF and GFR either 
at baseline or following BFTZ, although there was a trend towards lower RBF and lower GFR in the 
Hsd11b1/ mice at baseline (Figure 3).  The was no significant difference in heart weight between the 
two genotypes.  Urinary Na+ and Cl excretion both exhibited the expected increase following 
thiazide administration, but there were no differences between this response in Hsd11b1/ mice 
compared to wild-types, whether assessed as net urinary excretion (UNaV / UClV) or as fractional 
excretion (FENa, FECl) (Table 2B; Figure 3).  BFTZ induced a kaliuresis of greater magnitude in 
Hsd11b1/ mice than in wild-types (p < 0.05; Table 2B).   
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It is possible that the greater thiazide-induced kaliuresis in Hsd11b1-/- mice was the result of 
enhanced Na+ reabsorption in the distal nephron through the epithelial sodium channel, ENaC.  We 
therefore tested the effect of the ENaC inhibitor benzamil under renal clearance (Figure 1B).  This 
elicited a natriuresis that was no different in Hsd11b1-/- and wild-type mice (Figure 4).   
Urinary steroid excretion and adrenal morphology 
We sought to determine the consequences of global 11βHSD1 loss for urinary steroid excretion.  
Urine samples collected from the metabolic studies were used make a longitudinal assessment of 
steroid excretion.  There were no consistent genotype-specific differences in the urinary excretion of 
corticosterone or aldosterone (Figure 5).  As expected, aldosterone excretion was inversely correlated 
with dietary Na+ intake in both genotypes.  DOC (deoxycorticosterone) excretion was elevated 
approximately 2-fold in Hsd11b1/ mice; this difference was accentuated by high dietary Na+, which 
elevated DOC excretion in both genotypes (Figure 5C).   
Hsd11b1/ mice also exhibited a difference in adrenal morphology (Figure 6).  Compared to wild-
types, cells of the zona fasciculata (ZF) were larger in Hsd11b1/ mice – an effect most pronounced in 
the inner ZF (i.e. that part closest to the medulla).  No differences were apparent in the zona 
glomerulosa or in the adrenal medulla.   
Renin-angiotensin and nitric oxide systems 
There were no genotype-specific differences in the plasma concentrations of renin and 
angiotensinogen (AGT).  As expected, both compounds were suppressed by high dietary Na+ feeding 
(Figure 7AB).  Urinary excretion of nitrite and nitrate (NOx) varied in proportion to dietary Na+ 
intake; there were no genotype-specific differences (Figure 7CD).   
Gross renal structure and histology 
There was no difference in the ratio of kidney to body weight between genotypes: 4.9 ± 0.4 in WT 
vs. 5.3 ± 0.4 in Hsd11b1/ (mg kidney weight per g body weight; mean ± SD; n=13; p=0.11 by unpaired 
Student’s t-test).  Kidneys were fixed in situ by vascular perfusion, sectioned and stained with 
haematoxylin/eosin.  There were no gross differences in renal histology between genotypes (Figure 
8AB).  There was no evidence of chronic kidney disease (e.g. glomerulosclerosis, interstitial fibrosis, 
tubular atrophy) in Hsd11b1 mice/; nor was there any apparent expansion or atrophy of specific 
nephron segments.  We applied an immunohistochemical stain (anti-NCC) to label the distal 
convoluted tubule, as this segment is known exhibit structural plasticity in response to perturbations 
in Na+ homeostasis; the DCT appeared morphologically normal in Hsd11b1 mice/ (Figure 8C-F).  
NCC was associated with the apical membranes of DCT cells and displayed no major difference in 
distribution or intensity between genotypes.   
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Expression of tubular transporter proteins 
The abundance of key transporter proteins in whole kidney homogenates was determined by 
Western blot.  We applied this analysis to mice maintained on normal dietary Na+ and following 
dietary Na+ restriction, as our over-arching hypothesis was that Hsd11b1-/- mice have a tendency to 
renal salt-wasting.  We reasoned therefore that any perturbation in renal Na+ homeostasis would be 
most pronounced following Na+ depletion.   
We analysed two tubular sodium transporters known to be regulated by glucocorticoids (the Na-
K-2Cl co-transporter NKCC2 and NCC).  In the case of NCC, in addition to measuring the abundance 
of total protein, we measured that of a phosphorylated form that is associated with active NaCl 
transport (pT53-NCC).  There were no genotype-specific differences in the abundance of NKCC2, 
total NCC or pT53-NCC in kidneys harvested from mice maintained on a normal (0.2%) or low 
(0.026%) Na+ diet (Figure 9).   
Prompted by our finding of enhanced thiazide-induced kaliuresis in Hsd11b1-/- mice, we measured 
the abundance and predominant molecular mass of the gamma subunit of ENaC (ENaC-γ).  Channel 
activation is associated with cleavage of this subunit from a form that runs at c. 85 kDa on Western 
blot to one that runs at c. 70 kDa (Masilamani et al., 2002).  As expected, the 70 kDa band was stronger 
in mice maintained on a low Na+ diet.  However there was no difference in the total abundance of 
ENaC-γ (assessed by densitometry of all bands), nor in the abundance of the 85 kDa or 70 kDa 
isoforms in Hsd11b1-/- compared to wild-type mice on either diet (Figure 9).   
We also analysed the phosphorylation status of NDRG1 (n-myc downstream-regulated gene 1), an 
index of Sgk1 activity, itself a direct target of glucocorticoid signalling (Murray et al., 2004; Inglis et al., 
2009).  This was no different in the kidneys of Hsd11b1/ mice, compared to wild-types (on either a 
normal or low Na+ diet; Figure 9).   
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Discussion 
Our primary hypothesis was that Hsd11b1/ mice would display a propensity for renal Na+ and 
water loss, as a consequence of diminished glucocorticoid generation in the kidney.  The control of 
renal Na+ excretion is dominated by the RAAS, with glucocorticoids playing a modulatory role 
(Hunter et al., 2014b).  Therefore we anticipated that any phenotype would be subtle, and subject to 
compensatory changes in other natritropic neurohormonal control systems.   
Systemic and renal steroid metabolism 
We found increased urinary excretion of DOC in Hsd11b1 mice/, but excretion of corticosterone 
did not differ from wild-type mice.  DOC is a precursor of corticosterone, and both steroids are 
synthesised in the zona fasciculata under the control of ACTH (Al-Dujaili et al., 2009b).  Circulating 
levels of DOC and corticosterone thus usually increase or decrease in parallel.  We found cell 
hypertrophy in the zona fasciculata of Hsd11b1/ adrenal, consistent with increased production of 
DOC and / or corticosterone.  Circulating [corticosterone] is known to be elevated approximately 2-
fold in Hsd11b1/ mice (Kotelevtsev et al., 1997; Morton et al., 2004).  As has been argued before, this 
is presumably a result of a loss of normal 11βHSD1 activity in the hypothalamus and pituitary, 
blunting the negative feedback effect of circulating glucocorticoids on ACTH production (Kotelevtsev 
et al., 1997; Harris et al., 2001).  Human patients with genetic mutations inducing functional 11βHSD1 
deficiency also exhibit excessive ACTH-mediated adrenal steroid secretion, with consequent 
hyperandrogenism (Lavery et al., 2013).   
Urinary excretion of corticosterone will reflect circulating [corticosterone] and the combined 
activities of renal 11βHSD1 and 11βHSD2.  Our finding (that there is no difference in urinary 
excretion, despite evidence of increased corticosterone production) is compatible with the expected 
reduction in renal 11βHSD1 activity (assuming no difference in renal 11βHSD2).  The urinary 
excretion of corticosterone is diminished following the inhibition of renal 11βHSD1 in rat kidneys 
(Liu et al., 2008).   
Renal electrolyte excretion: net effects 
No significant urinary Na+ losses were observed in Hsd11b1/ mice – even when mice were 
transitioned to a low Na+ diet.  It is possible that no effect was seen because the elevated levels of 
circulating corticosterone compensated completely for absent renal 11βHSD1 activity, resulting in 
normal tissue levels of active glucocorticoid in the kidneys of Hsd11b1/ mice.  Furthermore, any 
natriuretic tendency may have been offset by increased mineralocorticoid activity from DOC (see 
below).  We found no differences in measures of RAAS and NO system activity in Hsd11b1/ mice, 
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arguing against any major compensatory adjustment in these regulators of vascular tone, renal Na+ 
excretion and ABP.   
It is possible that our metabolic cage data were subject to confounding stress effects.  We included 
a 5-day acclimatisation period, which should provide sufficient time for the stabilisation of urine 
output and urinary electrolyte excretion (Stechman et al., 2010).  However, mice housed in metabolic 
cages have been reported to display HPA axis activation (manifesting as elevated faecal excretion of 
corticosterone) that is sustained for up to 3 weeks (Kalliokoski et al., 2013).  Such an effect may have 
masked subtle differences in corticosterone excretion and renal fluid-electrolyte metabolism between 
the Hsd11b1/ and control groups.  However, there were no differences between these groups in 
basal urinary Na+ excretion (measured as UNaV or FENa) in our renal clearance study – i.e. in mice that 
were not subject to the stress of a metabolic cage.   
Renal electrolyte excretion: glomerular and tubular functions and molecular pathways 
Glucocorticoids are known to increase renal blood flow and glomerular filtration rate (Hunter et 
al., 2014b).  There was a trend towards a reduction in both parameters in Hsd11b1/ mice, but this did 
not reach statistical significance.   
It is possible that, even without any change in net urinary Na+ excretion, there was a change in the 
predominant site of Na+ reabsorption in the renal tubule.  For example, glucocorticoid-mediated 
increases in Na+ reabsorption in the distal tubule might be offset by a reduction in reabsorption in the 
proximal tubule.  We therefore assessed molecular surrogates for Na+ transport activity in the thick 
ascending loop of Henle (NKCC2 protein expression) and the DCT (NCC protein expression and 
phosphorylation).  These targets were chosen because their expression / activity are stimulated by 
glucocorticoids in rodent models (Mu et al., 2011; Frindt & Palmer, 2012).  We also assessed gross 
renal structure; glucocorticoid treatment can induce segment-specific changes in epithelial structure 
in the distal renal tubule of rabbits (Wade et al., 1979).   
We found no differences in gross renal structure, and no difference in the expression and / or 
phosphorylation status of NKCC2 and NCC in Hsd11b1/ mice, arguing against a shift in the 
distribution of renal Na+ transport along the nephron.  However, our renal clearance study did 
provide some evidence of altered electrolyte transport in the distal nephron.  Thiazide treatment 
elicited a kaliuresis of greater magnitude in Hsd11b1/ mice.  Thiazides stimulate K+ excretion 
because their action delivers a tubular Na+ load to the connecting tubules and collecting ducts, where 
Na+ reabsorption through ENaC generates a lumen-negative potential gradient that drives K+ 
secretion.  We found no evidence of enhanced ENaC activity in Hsd11b1-/- mice: the natriuretic effect 
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of benzamil was no greater than in wild-type mice and the proteolytic activation of ENaC-γ was not 
evident on Western blot.  Thus we presume that the enhanced kaliuresis observed in Hsd11b1-/- mice 
reflects the activity of either ROMK or the Na-K-ATPase in the distal nephron (although we have no 
data to support this contention).  Both of these molecules might be expected to be upregulated by the 
mineralocorticoid activity of DOC, which we detected at elevated levels in Hsd11b1/ mice.   
NDGR1 phosphorylation in whole kidney homogenates (an index of Sgk1 activation) was no 
different in Hsd11b1/ mice.  Sgk1 is a target of both mineralocorticoid (Chen et al., 1999) and 
glucocorticoid (Hunter et al., 2014b) signalling in renal tissue.  Our finding suggest that there is no 
significant net stimulation of corticosteroid-responsive pathways in the kidneys of Hsd11b1/ mice, 
but does not preclude relative differences in glucocorticoid or mineralocorticoid signalling in defined 
regions of the kidney.   
Our failure to detect a striking water-electrolyte phenotype is in accordance with the known 
effects of glucocorticoids on renal tubular Na+ transport.  Glucocorticoids can stimulate Na+ 
reabsorption via a number of pathways in the proximal and distal renal tubule, but their effects are 
often only evident when glucocorticoids are present in excess and they tend to modulate transport 
processes that are under the dominant control of another system (e.g. the RAAS and / or sympathetic 
nervous system) (Hunter et al., 2014b).  It is possible that any effect is masked by a compensatory 
increase in corticosterone excretion in the global Hsd11b1 knockout, and it would be interesting to 
examine renal Na+ transport in a kidney-specific knockout.  It is also possible that glucocorticoids 
only exert significant effects on renal Na+ transport when they are present in excess.  Thus, loss of 
renal 11βHSD1 may not yield a discernible phenotype, whereas 11βHSD1 over-expression might.   
Perspective: implications for clinical medicine 
Excess glucocorticoids cause obesity, insulin resistance, diabetes mellitus, hyperlipidaemia and 
hypertension.  These traits, collectively the “metabolic syndrome”, are major risk factors for 
cardiovascular morbidity and mortality.  Adverse cardiometabolic consequences may also be 
associated with “replacement” doses of therapeutic glucocorticoid, perhaps because these perturb 
ultradian rhythms in glucocorticoid signalling (Henley & Lightman, 2014).   
The actions of 11βHSD1 in liver and adipose tissue have been extensively studied.  Over-
expression at these sites gives rise to salt-sensitive hypertension and activation of the renin-
angiotensin-aldosterone system (Masuzaki et al., 2003; Paterson et al., 2004).  There is an emerging 
hypothesis that 11βHSD1 over-activity is central to the pathogenesis metabolic syndrome (Anagnostis 
et al., 2009) and a corresponding interest in 11βHSD1 inhibitors as therapeutic agents in the metabolic 
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syndrome and type 2 diabetes mellitus (Tahrani et al., 2011; Anagnostis et al., 2013).  However, the 
potential contribution of renal 11βHSD1 to the pathogenesis of Na+-retention and hypertension in the 
metabolic syndrome has not – to our knowledge – been hitherto explored; nor have the potential 
consequences of renal 11βHSD1 inhibition.  Our results suggest that renal 11βHSD1 deficiency does 
not exert significant effects on systemic blood pressure and Na+ homeostasis.  The clinical use of 
11βHSD1 inhibitors would not therefore be predicted to confer significant off-target effects on renal 
Na+ transport.  No such adverse effects were detected in a clinical trial of 11βHSD1 inhibition in type 
2 diabetes mellitus (Rosenstock et al., 2010).   
Conclusions and implications for basic renal physiology 
We found no physiologically significant effect of global 11βHSD1 deletion on renal Na+ excretion, 
arterial blood pressure, kidney function or renal perfusion.  We conclude that any effect of 11βHSD1 
on renal Na+ excretion is subtle.   
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Table 1.  Baseline characteristics of experimental cohorts.  Data presented as mean ± standard 
deviation.  Comparisons between genotypes are by unpaired t-tests; significant p-values are 
underlined.   
 
cohort n =  age  
/ days 
body weight  
/ g 
kidney weight  
/ mg 
kidney:BW 
ratio / mg per g 
 
Metabolic study: high Na
+
 group 
WT 11 81 ± 3.3 25.0 ± 1.4 160.9 ± 9.9 6.65 ± 0.41 
Hsd11b1
 –/–
 11 91 ± 11.4 27.7 ± 2.5 172.9 ± 13.5 6.88 ± 0.88 
p =   0.006 0.027 0.438 
 
Metabolic study: low Na
+
 group 
WT 6 97 ± 3.7 26.8 ± 2.7 156.5 ± 9.3 6.41 ± 0.55 
Hsd11b1
 –/–
 6 103 ± 12.0 31.1 ± 3.5 190.5 ± 22.2 6.54 ± 0.44 
p =    0.040 0.006 0.647 
 
Renal clearance study: effect of bendroflumethiazide 
WT 7 214 ± 82.5 33.9 ± 5.0 173.5 ± 19.3 5.16 ± 0.44 
Hsd11b1
 –/–
 8 164 ± 65.9 34.2 ± 6.4 179.0 ± 17.3 5.34 ± 0.84 
p =   0.912 0.574 0.620 
 
Renal clearance study: effect of benzamil 
WT 6 126 ± 2.7 31.4 ± 1.7 304.7 ± 35.2 9.68 ± 0.78 
Hsd11b1
 –/–
 5 101 ± 9.9 29.2 ± 1.1 276.6 ± 14.7 9.46 ± 0.46 
p =  
 
0.037 
0.132 0.594 
 
Histology study 
WT 3 174 ± 1.5 30.7 ± 3.3   
Hsd11b1
 –/–
 3 191 ± 0.6 31.7 ± 1.0   
p =   0.631   
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A 
 
 
WT Hsd11b1
 –/–
 p 
PNa mM 146.6 ± 2.4 148.1 ± 2.7 0.2604 
PK mM 3.69 ± 0.28 3.50 ± 0.35 0.2785 
PCl mM 118.3 ± 3.5 118.6 ± 4.7 0.8794 
Hct % 42.0 ± 2.4 40.9 ± 2.5 0.3876 
 
B 
BASELINE BFTZ p-values 
 WT Hsd11b1
 –/–
 WT Hsd11b1
 –/–
 BFZ GT IA 
UV 
µL·min
-1
·g KW
-1
 
7.54 5.42 30.44 32.81 <0.0001 0.9651 0.5028 
(5.34 , 9.75 ) (3.15 , 7.96) (19.62 , 41.26) (23.70 , 41.91)    
UNaV 
µmol·min
-1
·g KW
-1
 
0.68 0.59 7.06 7.64 
<0.0001 0.7687 0.6895 
(-0.01 , 1.38) (0.17 , 1.01) (4.02 , 10.09) (5.16 , 10.12)    
UKV 
µmol·min
-1
·g KW
-1
 
1.77 1.17 2.24 2.74 0.0012 0.8279 0.0435 
(1.10 , 2.44) (0.78 , 1.55) (1.71 , 2.78) (2.06 , 3.43) 
   
UClV 
µmol·min
-1
·g KW
-1
 
0.57 0.37 5.24 5.55 <0.0001 0.9352 0.6612 
(-0.08 , 1.21) (0.19 , 0.54) (2.83 , 7.64) (3.80 , 7.29)    
FEK 
% 
42.8 41.1 57.2 68.0 
0.0002 0.4161 0.1515 
(33.6 , 52.1) (33.9 , 48.2) (40.8 , 73.6) (56.0 , 80.1)    
FECl 
% 
0.38 0.40 3.63 3.89 <0.0001 0.6624 0.6702 
(0.03 , 0.74) (0.22 , 0.58) (2.59 , 4.67) (2.97 , 4.67) 
   
 
 
Table 2.  Renal clearance data.  Hsd11b1–/– (n = 8) and wild-type (n = 7) mice were used in a renal 
clearance study as described in the main text.  A) Plasma electrolyte concentrations and haematocrit 
(HCT) in the terminal blood sample.  Data are presented as mean ± SD.  There were no significant 
differences between genotypes (by unpaired t-test).  B) Renal clearance parameters at baseline and 
following a bolus dose of bendroflumethiazide (BFTZ).  Data are presented as mean and 95 % CI.  UV, 
urine flow; UNaV, UKV and UClV, urinary excretion of Na+, K+ and Cl–; FEK and FECl, fractional 
excretion of K+ and Cl–.  p-values for comparisons between genotypes (GT) and baseline vs. after 
BFTZ made by 2-way ANOVA with repeated measures; IA = interaction.  p-values < 0.05 are 
underlined.   
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Figure 1.  Experimental protocols.  A) Time-course of experimental protocols for balance studies.  B) 
Time-course of renal clearance studies.  P1, P2, P3: plasma collections.  BFTZ: bendroflumethiazide 2 
mg per kg body weight administered as an intravenous bolus.  BZM: benzamil 2 mg per kg body 
weight administered as an intravenous bolus.  (NB BFTZ and BZM were used in separate 
experimental series; they were never administered together.)   
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Figure 2.  Water, sodium and potassium balance in Hsd11b1–/– and wild-type and mice.  Dietary 
intake and urinary and faecal excretion of water, Na+ and K+ were measured in metabolic cages.  
Balance data were calculated as the difference between dietary intake and total excretion (sum of 
urinary and faecal excretion).  All data were normalised to kidney weight (KW).  Mice were fed a 
baseline (0.2 % Na+) diet for four days, followed by high Na+ (2.1 %) or low Na+ (0.026 %) diet for eight 
days.  A – C) Response to high-Na+ diet (n = 11 Hsd11b1–/– + 11 wild-type).  D – F) Response to low-
Na+ diet (n = 6 + 6).  Data are presented as mean ± 95 % CI.  Comparisons between genotype (GT) and 
sodium intake (SI) were made by 2-way ANOVA; IA = interaction.  * p < 0.05 by post hoc Holm-Šídák 
test.   
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Figure 3.  Renal clearance data: effect of bendroflumethiazide.  Hsd11b1–/– (n = 8) and wild-type (n = 
7) mice were used in a renal clearance study as described in the main text.  Recordings were made 
during a baseline period and after the intravenous administration of bendroflumethiazide (BFTZ), 2 
mg per kg body weight.  A) Mean arterial blood pressure, MABP.  B) Renal blood flow, RBF.  C) 
Glomerular filtration rate, GFR.  D) Fractional excretion of Na+, FENa.  Data are presented as mean ± 95 
% CI.  Comparison between genotypes (GT) and baseline vs. after BFTZ were made by 2-way 
ANOVA with repeated measures; IA = interaction.  There were no significant differences between 
genotypes.   
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Figure 4.  Renal clearance data: effect of benzamil.  The natriuretic effect of benzamil (BZM) was 
tested in a renal clearance study.  BZM was administered intravenously at a dose of 2 mg per kg body 
weight to Hsd11b1-/- (n = 5) and wild-type (n = 6) mice.  The fractional excretion of Na+ (FENa) was 
determined before and after BZM.  Data are presented as mean ± 95 % CI.  Comparison between 
genotypes (GT) and baseline vs. after BZM were made by 2-way ANOVA with repeated measures; IA 
= interaction.  There were no significant differences between genotypes. 
 
 
  
  
This article is protected by copyright. All rights reserved.   27 
 
Figure 5.  Longitudinal urinary steroid excretion.  A & D) Urinary corticosterone excretion in 
response to high- and low-Na+ diet respectively (n = 3 Hsd11b1–/– + 3 wild-type).  B & E) Urinary 
aldosterone excretion on high- and low-Na+ diet respectively (n = 3 + 3).  C & F) Urinary DOC 
excretion on high- and low-Na+ diet respectively (n = 3 + 3).  Data are presented as mean ± 95% CI.  
Comparisons between genotype (GT) and sodium intake (SI) were made by 2-way ANOVA with 
repeated measures; IA = interaction.  * p < 0.05 between genotypes by post hoc Holm-Šídák test.  
(Aldosterone results were missing for day 4 on high Na+ and day 11 on low Na+; these data were 
excluded from the ANOVA.)   
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Figure 6.  Cross-sectional area of adrenal cells in Hsd11b1–/– and wild-type mice.  Adrenal glands 
were harvested from Hsd11b1–/– and wild-type mice maintained on normal- (0.2 %) and low- (0.026 
%) Na+ diets for 8 days.  Mean cell size was measured in A) the zona glomerulosa of the adrenal 
cortex; B) outer zona fasciculata; C) inner zona fasciculata and D) the adrenal medulla.  Data are 
presented as mean ± 95 % CI.  Comparison between genotype (GT) and sodium intake (SI) were made 
by 2-way ANOVA; IA = interaction.  E) – H) Representative images of adrenal sections, stained with 
haematoxylin and eosin.  Scale-bars are 100 microns.   
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Figure 7.  Activity of renin-angiotensin and nitric oxide systems.  A) Plasma renin concentration in 
Hsd11b1–/– mice on normal (n = 9) and high (n = 5) Na+ diet and wild-type mice on normal (n = 13) and 
high (n = 5) Na+ diet.  B) Plasma angiotensinogen concentration in the same experimental groups (n = 
8, 4, 10 and 4 respectively).  C & D) Urinary NOx excretion (representative of total body NO 
production) in Hsd11b1–/– and wild-type mice on high and low Na+ diet respectively (n = 5 for each 
experimental group).  Data are presented as mean ± 95 % CI.  Comparison between genotype (GT) 
and sodium intake (SI) were made by 2-way ANOVA; IA = interaction.   
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Figure 8.  Renal histology and NCC expression by immunohistochemistry.  A & B) Renal cortex 
(H&E stain) in wild-type and Hsd11b1–/– mice respectively.  No gross changes in renal histology were 
apparent in Hsd11b1–/– mice (n = 3 for each genotype); representative images are shown.  C & D) 
Low-power view of immunohistochemical stain for NCC in renal cortex of wild-type and Hsd11b1–/– 
mice respectively.  E & F) High-power view of immunohistochemical stain for NCC in renal cortex of 
wild-type and Hsd11b1–/– mice respectively.  NCC was detected (as expected) in the apical cell 
membrane of the distal convoluted tubule.  The distribution did not differ between genotypes (n = 3 + 
3); representative images are shown.   
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Figure 9.  Immunoblot analysis in whole kidney homogenates from Hsd11b1–/– and wild-type mice.  
A) Densitometry analysis of immunoblots for total NCC (t-NCC), the phosphorylated form pT53-
NCC, NKCC2 (t-NKCC2), ENaC-γ and total (t-) and phosphorylated (p-) NDRG1.  Whole kidney 
homogenates were prepared from Hsd11b1–/– (n = 6) and wild-type mice (n = 6) maintained on normal 
(0.2 %) Na+ diet (cohort 2 from the metabolic study).  After correction with a loading control 
(Coomassie-stained band), density was normalised so that for each target protein, the wild-type 
group had a mean density of 1.0.  For ENaC-γ, densitometry data are presented for the sum of all 
bands.  B) Densitometry analysis applied to immunoblots of kidney homogenates from mice 
maintained on a low (0.026 %) Na+ diet (n = 6 for each genotype).  Data are presented as mean ± 95 % 
CI.  There were no significant differences between genotypes in either the normal or the low Na+ 
cohort (by unpaired t-test).  No inferences were drawn between blots – i.e. between normal and low-
Na+ groups.  C) Representative immunoblots; the Coomassie-stained gel used as a loading control is 
shown below each blot.  Size markers are in kDa. 
 
